The Wegovy ladder takes 16 weeks before the dose actually works. That's not slow. That's the entire trick.

You picked up your first pen. 0.25mg, weekly. You read the label, did the math, and felt scammed.

Sixteen weeks before you hit the dose that does anything? Why?

Here's what your prescriber didn't have time to explain.

The 0.25mg dose was never meant to make you lose weight.

The STEP 1 trial — the one that got Wegovy approved — published an average 14.9% body weight loss at 68 weeks. That number is at 2.4mg. The maintenance dose. The top of the ladder.

The 0.25mg starter dose? Early dose-finding studies (and the patterns echoed in STEP-program subgroup data) point to roughly 2-3% weight loss across an 8-week window at this dose — and most of that is GI-driven appetite suppression, not the receptor effect they actually want. It's the dose that gives you side effects without the appetite payoff. By design. The receptor is engaging — semaglutide binds GLP-1 even at 0.25mg — but engagement isn't enough. You need saturation, and 0.25mg is nowhere near it.

Then why give it?

Because the alternative — starting people directly at the higher doses — caused most early participants to wash out from nausea, vomiting, and diarrhea. The pattern shows up across the GLP-1 dose-finding literature (Bettge 2017; Wharton 2022): no titration, half-or-more dropout. The drug works. People couldn't take it.

So Novo Nordisk built the ladder backward from a tolerability problem, not a clinical one. The first four weeks aren't therapy. They're a runway.

Your gut is being rewired. Slow is the protocol.

Semaglutide doesn't melt fat. It binds GLP-1 receptors in the brainstem and gut, slowing gastric emptying by 30-50% and dampening the hunger signal from the arcuate nucleus. Food sits in your stomach longer. You feel full on less. Your reward circuit stops screaming at 11pm for ice cream.

All of that requires your enteric nervous system — the network of neurons lining your gut — to recalibrate.

Move too fast and that nervous system revolts: nausea, vomiting, constipation that won't budge for a week, the specific pain people describe as "like swallowing a brick."

The ladder isn't a marketing schedule. It's a habituation curve.

Your gut is rebooting under new firmware. Boot it too fast and it crashes.

The five steps and what each one is actually doing.

Here's the FDA label, decoded:

Note that Ozempic — the same molecule, sold for diabetes — caps at 2.0mg. Wegovy goes higher because obesity needs more receptor saturation than glycemic control does. You're not climbing toward a normal dose. You're climbing toward one deliberately set above any normal therapeutic dose for diabetes — supratherapeutic in plain English.

That's why the climb takes four months. You're not waiting for paperwork. You're letting your gut catch up to a dose Ozempic patients never see.

The most useful page in the label nobody reads.

The Wegovy label has one sentence buried under "Dosage and Administration" that prescribers gloss over and patients never see:

"If patients do not tolerate a dose during dose escalation, consider delaying dose escalation for 4 weeks."

In plain English: you can stop climbing. You can hold a dose for an extra month. You can step back down a rung if symptoms blow past your manageable line.

The most common pattern I see in the data: somebody hits 1.0mg, gets walloped by week-2 nausea, white-knuckles through assuming the protocol is rigid, and quits the drug entirely by week 10. They never knew they could have held 0.5mg for eight weeks instead of four. Or dropped back to 0.5mg and tried the climb again next month.

The ladder is a guide. Hold and step-back are the safety valves. Use them.

When to step back: the 7/10 rule.

Most "I can't tolerate this" decisions get made on the worst day of the week — usually Cmax day (the peak drug level — for once-weekly semaglutide, that's about 24-48 hours after the injection). Don't decide on that day.

The decision rule, by week-of-cycle and current rung:

This isn't pulled from nothing — it's the operational pattern you'll find in the GLP-1 management literature (Wharton 2022, Bettge 2017). The 4-week hold is the consensus floor for receptor adaptation.

Where most weight loss actually happens.

Here's the part nobody tells you upfront: the maintenance dose does most of the work.

Plot the STEP 1 weight curve and you'll see something obvious. Most participants lost 2-4% during the four-month climb. The remaining ~10% came afterward — during months 5 through 17, all at 2.4mg.

Translation: the climb is not the diet. The climb is the price of admission. The diet starts at week 17.

This matters for two practical reasons:

1. If you're judging the drug at week 8, you're judging the runway, not the flight. Don't.
2. If you stop at 1.0mg or 1.7mg because you "feel okay there," you're capping yourself at maybe half the trial's full result. Some people are fine with that — fewer side effects, lower cost, lower expectations. Just know what you're choosing.

And about the 4-month bill.

Brand Wegovy retails at $1,349-1,800/month through NovoCare or telehealth platforms. Across the 16-week climb plus 12 weeks of maintenance, that's a $9,400-12,600 first-year cost before insurance.

LiberaCure generic semaglutide injection — same molecule, full pen lineup (0.25, 0.5, 1.0, 1.7, 2.4mg) — runs $80-150/month depending on the dose tier. Same first year: $960-1,800.

What you're not paying for at the lower price: the NovoCare app, the U.S. cold-chain courier, the brand-name pen device (the auto-injector mechanism is functionally the same), and the U.S. patent runtime. The Indian launch went live March 2026 because the relevant patent doesn't extend there. The reason our markup tier sits where it does is upstream of all that — crypto-only checkout (no card-network fees), no U.S. customer-acquisition spend, no U.S. corporate overhead.

Cold-chain handling — the part that actually matters for an injectable peptide — is preserved end-to-end through licensed pharmacies. We've shipped through this lane long enough to verify the chain. (For details on what to ask any GLP-1 supplier about cold-chain, see our GI side-effects management guide.)

For reference on policy: standard lead time 2 weeks, 2-4 weeks with customs variance. Tracking active 24-48h after dispatch. If a pen shipment is lost in transit, we reship free — twice. Crypto refund (BTC/ETH/USDT) on third failure. Email reply 24-48h ([email protected]); no live chat, no phone. Crypto means no chargeback, so this explicit reship-then-refund is our equivalent of dispute resolution. Different mechanism than a card chargeback, comparable outcome if the policy is honored.

Month-by-month: what to actually do.

One must-do per month. The optional items are leverage, not requirements.

Month 1 (Weeks 1-4): 0.25mg priming

• Must-do: Inject same day, same time each week. Routine over optimization.
• Optional: Cmax is T+24-48h. Light, low-fat meals on those two days.
• Optional: Symptom journal — one 1-10 number for nausea / appetite / bowel, daily. Tedious; only way to know if month 2 is actually worse or just newer.
• Note: Don't expect weight loss this month. The dose isn't measuring you.

Month 2 (Weeks 5-8): 0.5mg

• Must-do: Step up only if month 1 Cmax-day symptoms stayed under 5/10. Otherwise hold 0.25mg another 4 weeks.
• Optional: Magnesium citrate 200-400mg/night clears most of the constipation that shows up here.
• Optional: First weigh-in worth recording — end of week 8.

Month 3 (Weeks 9-12): 1.0mg

• Must-do: This is the dropout cluster. If month 2 symptoms held at 4-6/10, hold 0.5mg another month before climbing — don't whitewash through.
• Optional: Sulfur burps common here. Famotidine 20mg AM helps about 60% of people.
• Optional: Lab check around week 11 — A1c, lipid panel, basic metabolic. Baseline before maintenance.

Month 4 (Weeks 13-16): 1.7mg

• Must-do: If symptoms blow past 7/10 here, step back to 1.0mg for a month before retrying. Don't quit the protocol.
• Optional: Track week-16 weight against baseline. 5-9% loss is on-curve. Flat 1-2% is the prescriber conversation about whether the climb makes sense for you.

Month 5+ (Weeks 17 onward): 2.4mg maintenance

• Must-do: Stay at 2.4mg for the duration of treatment. This is where most of the weight loss actually happens — months 5-12 are the curve.
• Optional: Plateau check at month 9. Stalled for 8+ weeks despite full adherence is the conversation about adding metformin, switching to tirzepatide, or accepting the new setpoint.
• Note: Stopping semaglutide cold reverts about 67% of weight loss within 12 months (more on this). The climb is the easy decision. The exit is the harder one.

A note on bias.

We route semaglutide injection orders. Be aware of that.

LiberaCure routes orders to licensed personal-import pharmacies. Noveltreat (by Sun Pharma) is one of the products we ship in this category — full ladder pens, 0.25 through 2.4mg, mirroring the Wegovy lineup. So we have a financial reason to want this article to lead you toward "give it a try" — and to keep filling for the maintenance year that pays the bills.

Read this with that in mind. The protocol above is what I'd tell a friend, not what maximizes reorder rate. The 4-week hold and step-back rules cost us reorder velocity. They're in here anyway because skipping them is how people quit the drug entirely.

Sources:

• Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med 2021;384:989-1002. PMID 33567185
• FDA Wegovy prescribing information, NDA 215256, current revision. Section 2.2 Dosage and Administration; Section 6.1 Adverse Reactions.
• Wharton S et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity. Postgrad Med 2022;134(1):14-19.
• Bettge K et al. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab 2017;19(3):336-347.
• DCGI / CDSCO public register, Sun Pharma Noveltreat launch, March 2026.
• NovoCare and U.S. telehealth pricing, April 2026.

— LiberaCure editorial. We route generic medication through licensed personal-import pharmacies. We don't dispense, prescribe, or warehouse. Read more about why.